解读与TP53致病变体相关的双重临床实体:来自法国实验室53085个HBOC小组分析的见解

Edwige Kasper1, Flavie Boulouard2,3, Noémie Basset4

  • 1Department of Genetics, Univ Rouen Normandie, Normandie Univ, Inserm U1245, and CHU Rouen, Rouen, France.

概括

TP53致病变体有助于遗传性乳腺和卵巢癌 (HBOC) 的倾向. 变异型影响表型,区分临床Li-Fraumeni综合征 (LFS) 与TP53相关的乳腺癌.

相关概念视频